Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPMS-02
- Development stage
- Preclinical
- Lead developer
- Lysat Pharma
- Modality
- Cell Therapies
01
Overview
LPMS-02 is a preclinical biologic candidate being developed by Lysatpharma for the treatment of Multiple Sclerosis (MS). It is a lysate-based cell preparation consisting of bioactive components extracted from specific cell sources using a patented technology. This approach aims to harness the immunomodulatory and regenerative properties of cell-derived factors while avoiding the complexities and safety concerns associated with live cell transplantation. Although the specific molecular targets of LPMS-02 have not been disclosed, the therapy is designed to address the inflammatory and neurodegenerative aspects of MS by utilizing the therapeutic potential of cell-free bioactive components.
Beyond the preview
Go deeper on LPMS-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPMS-02.